Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Regeneron Pharmaceuticals moved higher after promising results from a clinical trial of Dupixent for the treatment of a rare ...

Launched in October by Leerink Partners, CPE evaluates the long-term societal impact of healthcare innovations, aiming to go beyond typical cost-effectiveness models by assessing therapies not ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

The substantial revenues of over 13 billion euros from Dupixent alone reveal a high ceiling ... As Sanofi will be operating at the application layer of AI models, the company will capture all ...

Regeneron Pharmaceuticals moved higher after promising results from a clinical trial of Dupixent for the treatment ... softening demand for the company's Model 3 and Model Y vehicles.

The model used to summarize this release may make ... Phase 1b head-to-head study vs. DUPIXENT supported by successful completion of preclinical combination toxicology studies and positive APG990 ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...